A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients.

NCT07095114 | Recruiting

• 1 other identifier: 2025-034
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this clinical trial is to learn if tattoos applied with Magic Ink is as safe as commercially available standard tattoo ink for the purpose of radiation in women with breast cancer undergoing radiation treatment. The main questions are:

• Is the Magic Ink as safe as standard tattoo ink
• Does Magic Ink continue to function and remain visible for radiation therapists during the treatment Participants will be consented and given a skin assessment. Once enrolled participants will be administered the Magic Ink tattoo instead of the standard tattoo ink in preparation for their radiation treatment. Participants will also complete a survey regarding body image. Skin assessment will occur again after the first week of radiation and at 3 months later. Throughout the radiation therapy the medical physicist will complete surveys about ease of set-up of the equipment.

Conditions

Ductal Carcinoma in Situ; Stage I Breast Cancer; Stage II Breast Cancer; Stage III Breast Cancer

Outcome Measures

Primary Outcomes (1)

• Safety of Magic Ink

  Number of participants with treatment related adverse events as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v5.0)

  3 months after completion of Radiation Therapy

Secondary Outcomes (2)

• Efficacy of Magic Ink

  3 months after the completion of Radiation Therapy

• Body Image Score

  3 months after the completion of Radiation Therapy

Study Arms (1)

Magic Ink tattoo

EXPERIMENTAL

Magic Ink tattoo ink which is only visible when exposed to ultraviolet light will be used to mark radiation guidance

Other: Magic Ink

Interventions

Magic Ink OTHER

A novel ink that is only visible when exposed to Ultraviolet light and can be hidden using white light will be inserted into the dermis to tattoo a radiation guidance tattoo into the skin of the participant

Magic Ink tattoo

Eligibility Criteria

• Age: 18 Years+
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Participant must have histologically or cytologically confirmed stage 0 ductal carcinoma in situ (DCIS), I, II or III breast cancer and be planning to undergo radiation therapy (RT) after surgery
• Participants must be 18 years of age or older
• Participant must be able to understand a written informed consent document and be willing to sign it
• Participant must be assigned female at birth
• Participant must have a Karnofsky performance score of greater than or equal to 70%
• Women of child bearing potential must agree to avoid becoming pregnant through defined periods during the course of RT and must meet one of the following:
• Surgically sterile (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy
• Post-menopausal, defined as no menses for at least 12 months prior to the screening visit without alternative medical causation
• Agree to practice true abstinence from sexual intercourse
• Not in a sexual relationship in which the may become pregnant (i.e., same-sex relationship)
• If they are childbearing potential, agree to use at least one highly effective and at least one additional method of contraception.
• For the first six participants only: Participant must have a Fitzpatrick Skin Tone Scale of 5 or 6

You may not qualify if:

• Participants who have received prior radiation treatment to the affected breast.
• Participants with a history of allergic reaction or hypersensitivity attributed to any tattoo ink
• Participants with active chronic skin diseases such as psoriasis. Participants with inactive or controlled skin diseases are eligible for this study
• Participants that are pregnant or breastfeeding. If a participant wishes to participate in this study, breastfeeding should be discontinued
• Participants with a BMI greater than 44.5 as calculated within six months prior to the starting of the study. If there are multiple BMI measurements available in the chart, the most recent will be used to determine eligibility.

Sponsors & Collaborators

• Barbara Ann Karmanos Cancer Institute: lead

Study Sites (1)

Karmanos Cancer Institute

Detroit, Michigan, 48201, United States

RECRUITING

MeSH Terms

Conditions

Carcinoma, Intraductal, Noninfiltrating; Breast Neoplasms

Condition Hierarchy (Ancestors)

Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Breast Carcinoma In Situ; Carcinoma in Situ; Neoplasms, Ductal, Lobular, and Medullary; Neoplasms by Site; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Study Officials

• Michael Dominello, DO

  Wayne State University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Michael Dominello, DO

CONTACT

3135769546; Mdominel@med.wayne.edu

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: July 15, 2025
• First Posted: July 31, 2025
• Study Start: August 18, 2025
• Primary Completion (Estimated): August 8, 2026
• Study Completion (Estimated): August 8, 2026
• Last Updated: September 18, 2025

Record last verified: 2025-09

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)